Understanding Nurtec Patient Assistance Options For Migraine Treatment

The provided source material is insufficient to produce a 2000-word article. Below is a factual summary based on available data.

NURTEC ODT is a prescription medication containing rimegepant sulfate, a calcitonin gene-related peptide receptor antagonist. Each orally disintegrating tablet contains 85.7 mg rimegepant sulfate, equivalent to 75 mg rimegepant free base. The medication is indicated for the acute treatment of migraine with and without aura in adults.

For patients who have been prescribed NURTEC but face financial challenges, Pfizer offers a Patient Assistance Program that may provide the medication at no cost to eligible individuals. To qualify, patients must be at or below 300% of the Federal Poverty Level, adjusted for family size. Additional eligibility criteria apply, and patients can contact the program directly at 1-866-473-0088 for more information.

Clinical trials have demonstrated NURTEC ODT's efficacy in treating migraine. In a randomized, double-blind, placebo-controlled study (Study 1, NCT03461757), patients receiving 75 mg of NURTEC ODT showed statistically significant improvements compared to placebo in: - Pain freedom at 2 hours - Most bothersome symptom freedom at 2 hours - Pain relief at 2 hours (59.3% vs. 43.3%) - Sustained pain freedom 2-48 hours (13.5% vs. 5.4%) - Reduced use of rescue medication within 24 hours (14.2% vs. 29.2%) - Improved function at 2 hours after dosing

For the preventive treatment of episodic migraine, a 12-week, double-blind treatment period showed that 370 patients receiving one 75 mg dose of rimegepant every other day demonstrated safety and efficacy. In this study, approximately 81% were female, 80% were White, 17% were Black, and 28% were Hispanic or Latino.

The most common adverse reaction reported in clinical trials was nausea, occurring in 2% of patients who received NURTEC ODT compared to 0.4% of patients who received placebo. Other potential adverse effects include hypersensitivity reactions, hypertension, and Raynaud's phenomenon.

NURTEC ODT has specific administration instructions and precautions. The recommended dose for acute treatment is 75 mg taken orally, as needed, with a maximum dose of 75 mg in a 24-hour period. For preventive treatment, the recommended dosage is 75 mg taken orally every other day. Patients should avoid concomitant administration with strong inhibitors of CYP3A4 and should avoid another dose within 48 hours when administered with moderate inhibitors of CYP3A4.

The medication is available as white to off-white, circular, orally disintegrating tablets that are debossed with a specific symbol. Each carton contains a blister pack of 8 tablets. Patients should not remove the blister from the outer aluminum pouch until ready to use the tablet.

Unlike traditional free sample programs, the NURTEC Patient Assistance Program requires a valid prescription from a healthcare provider and verification of financial eligibility. The program is specifically designed for patients who have been prescribed NURTEC but may face financial barriers to accessing the medication.

Sources

1. NURTEC ODT Prescribing Information
2. Nurtec Patient Assistance Program